Partial MHC/Neuroantigen Peptide Constructs: A Potential Neuroimmune-Based Treatment for Methamphetamine Addiction

Jennifer M. Loftis1,3*, Clare J. Wilhelm1,3, Arthur A. Vandenbark1,4,5, Marilyn Huckans1,2,3

1 Research and Development, Portland VA Medical Center, Portland, Oregon, United States of America, 2 Behavioral Health & Clinical Neurosciences Division, Portland VA Medical Center, Portland, Oregon, United States of America, 3 Department of Psychiatry, School of Medicine, Oregon Health and Science University, Portland, Oregon, United States of America, 4 Department of Neurology, School of Medicine, Oregon Health and Science University, Portland, Oregon, United States of America, 5 Department of Molecular Microbiology and Immunology, School of Medicine, Oregon Health and Science University, Portland, Oregon, United States of America

Abstract

Relapse rates following current methamphetamine abuse treatments are very high (~40–60%), and the neuropsychiatric impairments (e.g., cognitive deficits, mood disorders) that arise and persist during remission from methamphetamine addiction likely contribute to these high relapse rates. Pharmacotherapeutic development of medications to treat addiction has focused on neurotransmitter systems with only limited success, and there are no Food and Drug Administration approved pharmacotherapies for methamphetamine addiction. A growing literature shows that methamphetamine alters peripheral and central immune functions and that immune factors such as cytokines, chemokines, and adhesion molecules play a role in the development and persistence of methamphetamine induced neuronal injury and neuropsychiatric impairments. The objective of this study was to evaluate the efficacy of a new immunotherapy, partial MHC/neuroantigen peptide construct (RTL551; pl-A\textsuperscript{b/m}MOG-35-55), in treating learning and memory impairments induced by repeated methamphetamine exposure. C57BL/6J mice were exposed to two different methamphetamine treatment regimens (using repeated doses of 4 mg/kg or 10 mg/kg, s.c.). Cognitive performance was assessed using the Morris water maze and CNS cytokine levels were measured by multiplex assay. Immunotherapy with RTL551 improved the memory impairments induced by repeated methamphetamine exposure in both mouse models of chronic methamphetamine addiction. Treatment with RTL551 also attenuated the methamphetamine induced increases in hypothalamic interleukin-2 (IL-2) levels. Collectively, these initial results indicate that neuroimmune targeted therapies, and specifically RTL551, may have potential as treatments for methamphetamine-induced neuropsychiatric impairments.

Introduction

Methamphetamine use causes long-term neuropsychiatric impairments (e.g., cognitive deficits, anxiety, and depression) that make addiction to this drug extremely challenging to treat [1,2]. A third to half or more of methamphetamine dependent adults experience persistent mood, anxiety, and other psychiatric disorders up to three years or longer into remission [3,4,5,6,7]. Relapse rates following current substance abuse treatments are very high (~40–60%) [8], and the neuropsychiatric impairments that arise and persist during remission from methamphetamine addiction likely contribute to these high relapse rates [5]. Pharmacotherapeutic development of medications to treat addiction has centered on neurotransmitter systems with only limited success, and there are no Food and Drug Administration (FDA) approved pharmacotherapies for methamphetamine addiction. Alternative treatment strategies are desperately needed.

Methamphetamine dependence is associated with long-term structural damage to regions of the brain that control cognitive and psychiatric function [9,10,11]. A growing literature demonstrates that methamphetamine alters peripheral and central immune functions [12–18] and that immune factors such as cytokines, chemokines, and adhesion molecules play a role in the development of methamphetamine induced neuronal injury and neuropsychiatric impairments [19,20,21]. The cellular source for these immune factors is currently under investigation, but glial cells are thought to play a significant role. Recent studies show that methamphetamine increases the expression of pro-inflammatory...
cytokines in astrocytes [18] and microglia [22,23]. These methamphetamine induced neuroimmune and neuropsychiatric impairments parallel immunological responses to other brain insults such as multiple sclerosis, stroke, and other drugs of abuse (e.g., compromised blood brain barrier resulting in increased permeability, increased activation of microglia and astrocytes producing pro-inflammatory cytokines, and damaged myelin/white matter tracks [9,24–36]). Collectively, these lines of evidence support the theory that methamphetamine induced dysregulation of immune function and immune factor expression play a key role in the development and maintenance of methamphetamine induced neuronal changes and neuropsychiatric dysfunction. Within this delicate balance of immune factors lies significant potential for intervention through targeted immunotherapies [37].

Because it has been previously shown that a partial MHC/neuroantigen peptide construct (RTL551; pI-Ab/mMOG-35-55) effectively reduces the inflammatory and behavioral effects of experimental models of multiple sclerosis and stroke [38,39,40,41], we hypothesized that partial MHCs could also effectively address the neuropathic effects of chronic methamphetamine addiction. The objective of this study was to evaluate the efficacy of multiple injections of RTL551 in treating learning and memory impairments induced by repeated methamphetamine exposure in mice. Experiments were performed using male C57BL/6j mice. Cognitive function was evaluated with the Morris water maze and CNS cytokine expression was measured by multiplex assay. The results of these experiments demonstrated that RTL551 has a treatment effect for memory impairments induced by repeated methamphetamine exposure, as demonstrated in two different mouse models of methamphetamine addiction (i.e., 4 mg/kg/day and 40 mg/kg/day).

**Materials and Methods**

**Animals**

Male C57BL/6j mice (between 6–12 weeks of age at the beginning of each experiment; approximately 20 g) were obtained from Jackson Laboratories (Bar Harbor, ME, USA). To monitor health status, mice were weighed and observed daily during the course of methamphetamine exposure and drug treatment. *Ethics statement: This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The Portland VA Medical Center Institutional Animal Care and Use Committee approved all experiments utilizing these mice.*

**Drugs**

Methamphetamine was obtained from the National Institute on Drug Abuse (NIDA) Drug supply program (i.e., NIDA Chemistry & Physiological Systems Research Branch). Methamphetamine was dissolved in 0.9% saline and stored at 4°C. The stock solution was stored for up to 10 days prior to administering doses to mice. Stock solutions were aliquoted as needed on the day of treatment. The partial major histocompatibility complex (MHC) constructs (pMHCs) were received from Drs. Gregory Burrows and Roberto Meza-Romero of the Oregon Health & Science University, Portland, OR. RTL551 consists of I-Ab MHC domains linked to the myelin oligodendrocyte glycoprotein (MOG)-35-55 peptide. The physical properties and mechanisms of action of RTLs (or pMHCs) have been described in detail previously [38,39,40,41,42]. Recombinant proteins (RTL551) were purified by fast protein liquid chromatography (FPLC) using a Source 30Q anion-exchange column run followed by a Superdex 75 size exclusion column run. Proteins were then dialyzed against 20 mM Tris-Cl buffer at pH 8.5, which removed the urea and allowed refolding of the recombinant proteins. Following dialysis, the proteins were concentrated by ultrafiltration cell through an ultrafiltration membrane with 10,000 molecular weight cut off limit. The final purified products were in 20 mM Tris-Cl buffer, pH 8.5 at a final concentration of 1.0 mg/ml quantified by amino acid analysis. Stock solutions of RTL were stored at −20°C until used and then stored at 4°C thereafter. Dilutions of stock solutions were made prior to administering diluted doses to mice and stored at 4°C.

**Behavioral testing**

Mice were evaluated for spatial learning and memory using the Morris water maze (MWM) as previously done [43], with procedures adapted from [44]. The water maze consisted of a round white plastic tub (1.22 m in diameter) filled with water made opaque by the addition of white tempera (non-toxic) paint. Within the tub, a round platform 0.5 m high and 0.13 m in diameter made out of transparent plastic was submerged just below the surface of the water. Animals received two days of visible platform training, followed by three days of hidden platform training. For visible platform trials, a 50 ml conical tube (Becton, Dickinson and Company, Franklin Lakes, NJ) labeled with bright laboratory tape was used to mark the submerged platform, and the platform was placed in each of the four quadrants of the water maze. Animals received three trials (spaced 8–10 min apart) at each visible platform location. Trials were 60 s from the time the animal was placed in the water maze, or until the animal located and climbed atop the platform. Animals that did not find the platform within 60 s were moved to the platform and held there for three seconds. Following the two days of visible platform training, animals received three days of hidden platform training. For these trials, the location of the platform was fixed and the 50 ml conical tube marking the platform removed. Hidden platform training was similar to visible platform training, with animals receiving six trials per day (broken into two sets of three trials with three hours separating each set of trials). Spatial learning and memory was assessed daily via a single probe trial that occurred 60 min after the last hidden platform training trial. The hidden platform was removed prior to the probe trials, and each probe trial lasted for 60 s. An additional probe trial administered 24 hr after the final hidden platform training session was used to assess long-term memory retention. Behavior was monitored using videotracking software [ANY-maze, Stoeling Co., Wood Dale, IL (Investigation of repeated methamphetamine exposure and RTL treatment on cognitive function); HVS Image 2020 Plus Tracking System, HVS Image Ltd., UK (Evaluation of binge methamphetamine exposure and RTL treatment on cognitive function)].

The primary dependent variable for this task was the amount of time animals spent in the target quadrant (the quadrant that was paired with the hidden platform) during probe trials. The amount of time spent in the target quadrants during probe trials is indicated by quadrant preference (% time) in Figures 1B and 2B. Latency or time to find the platform during the visible and hidden platform training trials was also measured and analyzed (Figs. 1A and 2A).

**Investigation of repeated methamphetamine exposure and RTL treatment on cognitive function**

The study design is outlined in Table 1. Male C57BL/6j mice (n = 32) were group housed (n = 4–5 per cage). Mice were randomly assigned to one of four groups: methamphetamine (Meth)-vehicle (Veh), Meth-RTL551, saline (Sal)-Veh, or Sal-
Animals received methamphetamine (4 mg/kg) or saline once daily [subcutaneously (s.c.)] for 15 consecutive days. During the last 7 days of methamphetamine exposure, animals were also administered (s.c.) RTL551 (0.1 mg/animal s.c.) or Veh (20 mM Tris, 10% w/v dextrose) (Intervention Phase). Mice were weighed daily during drug treatment and behavioral testing to monitor health status.

Because it is common for human patients with methamphetamine dependence to relapse or continue to use methamphetamine during substance abuse treatment [45], the methamphetamine exposed mouse groups continued to receive methamphetamine during the Intervention Phase. The Intervention Phase was accompanied by a Behavioral Testing Phase during which mice were evaluated for spatial learning and memory with the MWM (see Behavioral testing). On the MWM, a lack of preference for the target quadrant (i.e., no significant differences in terms of the time spent in each quadrant across quadrants) was interpreted as impaired spatial learning and memory and analyzed [46], as described under Statistical analysis.

Evaluation of binge methamphetamine exposure and RTL treatment on cognitive function and CNS cytokine expression

To more closely model the human experience and test the efficacy of RTL in reducing persistent methamphetamine-induced cognitive deficits, we assessed the effects of RTL treatment on cognitive function and cytokine expression when treatment was administered during remission from repeated binge exposure to methamphetamine. This models an ideal treatment strategy in humans where treatment is provided during early remission from addiction. Of note, the cognitive impairments resulting from repeated low dose regimens (e.g., 4 mg/kg for 15 consecutive days) attenuate in mice following the last methamphetamine exposure (unpublished observations); thus, a repeated low dose model does not...
Figure 2. Efficacy of RTL551 over vehicle in the treatment of methamphetamine induced spatial learning and memory impairments (n = 13–14 per group). (a) Training sessions: time spent finding the visible and hidden platforms. Statistical analyses revealed no significant treatment group differences across study groups in terms of the latency to find the platform during the visible platform training sessions [Days 1 and 2; p = 0.39 (Gaussian approximation)]. This demonstrated that the groups were not significantly different in terms of basic motor function and perceptual abilities after treatment. Similar analyses also revealed no significant differences across treatment groups in terms of latency to find the platform during the hidden platform sessions [Days 3–5; p = 0.39 (Gaussian approximation)], suggesting that all groups were able to learn the task. (b) Memory test: Quadrant preference during the Day 5 probe trial (3rd day of hidden platform training). Statistical analyses revealed significant differences between the target and the three non-target quadrants for the following treatment groups: 1) Sal-Veh: Target versus Quadrants 1 \( (p < 0.001) \), 2 \( (p < 0.01) \) and 3 \( (p < 0.05) \), 2) Meth-Veh: Target versus Quadrant 1 \( (p < 0.001) \), 3) Sal+RTL551: Target versus Quadrants 1 \( (p < 0.05) \), 2 \( (p < 0.01) \), and 3 \( (p < 0.01) \), 4) Meth+RTL551: Target versus Quadrants 1 \( (p < 0.001) \), 2 \( (p < 0.01) \) and 3 \( (p < 0.05) \). In the Meth+Veh group, the percent time spent in each of the quadrants was only statistically different between quadrant 1 and the target quadrant, indicating that methamphetamine had induced significant memory impairments in this group. However, in the Meth+RTL551 group, mice spent significantly more time in the target quadrant than in all three of the other quadrants, indicating that RTL had significantly attenuated the methamphetamine induced spatial memory impairments in this group. The inset graph illustrates the differences in preference for the target quadrant across all treatment groups. When comparing all treatment groups, there was not a statistically significant difference in preference for the target quadrant [Kruskal-Wallis test, \( p = 0.27 \) (Gaussian approximation)]. However, exploratory post-hoc analyses found a significant difference between Meth+Veh and Meth+RTL551 treatment groups [Mann-Whitney test, \( p = 0.034 \) (Gaussian approximation)].

doi:10.1371/journal.pone.0056306.g002

Table 1. Study Design: Investigation of repeated methamphetamine exposure and RTL treatment on cognitive function.

| Treatment Group (n) | Drug Exposure Phase (7 Days) | Intervention Phase* (8 Days) | Behavioral Testing Phase* (6 Days) |
|---------------------|------------------------------|-----------------------------|-----------------------------------|
| SAL+Veh (n = 8)     | SAL, 0.9%, s.c, once daily   | SAL, 0.9%, s.c, once daily; Tris-HCl, pH = 8.5, s.c, once daily | SAL, 0.9%, s.c, once daily; Tris-HCl, pH = 8.5, s.c, once daily |
| Meth+Veh (n = 8)    | Meth, 4 mg/kg, s.c, once daily | Meth, 4 mg/kg, s.c, once daily; Tris-HCl, pH = 8.5, s.c, once daily | Meth, 4 mg/kg, s.c, once daily; Tris-HCl, pH = 8.5, s.c, once daily |
| SAL+RTL551 (n = 8) | SAL, 0.9%, s.c, once daily   | SAL, 0.9%, s.c, once daily; RTL551, 100 μg, s.c, once daily | SAL, 0.9%, s.c, once daily; RTL551, 100 μg, s.c, once daily |
| Meth+RTL551 (n = 8) | Meth, 4 mg/kg, s.c, once daily | Meth, 4 mg/kg, s.c, once daily; RTL551, 100 μg, s.c, once daily | Meth, 4 mg/kg, s.c, once daily; RTL551, 100 μg, s.c, once daily |

*The Intervention and Behavioral Testing Phases overlapped such that MWM training began on the 4th day of the Intervention Phase. To avoid acute intoxication effects at the time of behavioral testing, mice performed water maze testing in the morning, with drug administration later in the day.

doi:10.1371/journal.pone.0056306.t001
mimic the persistent neuropsychiatric impairments seen in humans during remission from methamphetamine addiction [19] and does not provide a measurable signal to treat during a remission period. The study design for the evaluation of binge methamphetamine exposure and RTL treatment on cognitive function is outlined in Table 2. All mice were singly housed for seven days prior to methamphetamine exposure, and the mice remained housed so until the end of the experiment. Social isolation was introduced to provide the animals with a mild environmental stressor, which parallels the experience of human methamphetamine users. Social isolation also impacts drug and cognitive effects [47,48].

Two cohorts of mice (n = 32 per cohort) were used to evaluate the effects of binge methamphetamine exposure and RTL treatment on cognitive function. Mice were divided into each of the following four treatment groups: Meth-Veh, Meth-RTL551, Sal-Veh, or Sal-RTL551. Immediately following seven days of isolate housing, mice received repeated daily injections of methamphetamine (10 mg/kg per injection, s.c.), four times per day, with each treatment separated by two hours. Methamphetamine exposure was repeated for seven days, with treatments occurring every other day (i.e. methamphetamine exposure occurred on Mon, Wed, Fri, Sun, Tues, Thurs, and Sat). The first day after the methamphetamine treatment was completed, animals began MWM training, and daily treatment with RTL551 (0.1 mg/animal s.c.) or Veh (20 mM Tris, 10% w/v dextrose). RTL treatments were administered on five occasions and followed completion of each day’s MWM training.

CNS cytokine expression (cohort 1 only): Four days after completion of the MWM mice were euthanized via CO2 asphyxiation (for the determination of cytokine expression). Brains were collected and microdissected on ice; hypothalamus was collected and stored at −80°C. For multiplex determination of cytokine and chemokine expression, brain tissue was prepared based on the methods of Hulse et al., (2004) and as done in our laboratory [49,50]. Briefly, hypothalamic samples were thawed in cell lysis buffer (Bio-Rad; Hercules, CA), containing protease inhibitor cocktail (Bio-Rad) and 3 μl of a stock solution containing 500 mM phenylmethylsulfonyl fluoride in DMSO (Sigma). The samples were then homogenized (Pellet Pestle motor, Kontes) and centrifuged at 4500 x g for 15 min at 4°C. Supernatants were collected and used for multiplex immunomassays. Total protein concentration was determined using BCA (bicinchoninic acid) protein assay kits (Pierce) and absorbance reader (BioRad 680). A multiplex cytokine assay (Mouse Multiplex Cytokine kit, Millipore; Billerica, MA) was conducted to detect interferon-gamma (IFN-γ), IL-10, IL-1β, IL-2, IL-6, monocyte chemoattractant protein-1 (MCP-1 or CCL2), and tumor necrosis factor-alpha (TNF-α) levels.

### Results

**Investigation of repeated methamphetamine exposure and RTL treatment on cognitive function**

Mice exposed to methamphetamine or RTL treatment did not show any serious adverse effects or overt signs of ill health; Table S1 summarizes body weight information for the experiments. Statistical analyses revealed no significant treatment group differences across study groups in terms of the latency to find the platform during the visible platform training sessions [Days 1 and 2; p = 0.39 (Gaussian approximation)] (Fig. 1A). This demonstrated that the groups were not significantly different in terms of basic motor function and perceptual abilities after treatment. Similar analyses also revealed no significant differences across treatment groups in terms of latency to find the platform during the hidden platform sessions [Days 3–5; p = 0.39 (Gaussian approximation)], suggesting that all groups were able to learn the task.

Methamphetamine exposure induced significant spatial memory impairments in mice. Immunotherapy with RTL significantly attenuated methamphetamine induced spatial memory impairments in mice as measured by quadrant preference during the final probe trial (i.e., 24 hours after the completion of the Intervention Phase) (Fig. 1B). Friedman and Dunn post hoc tests revealed the following differences between the target and the three non-target quadrants: 1) Sal+Veh: Target versus Quadrants 1, 2, and 3 (p<0.05), 2) Sal+RTL551: Target versus Quadrants 1 and 2 (p<0.05), and 3) Meth+RTL551: Target versus Quadrants 1 and 2 (p<0.05). In the Meth+Veh group, the percent time spent in each of the quadrants was not statistically different across quadrants, indicating that metham-

### Table 2. Study Design: Evaluation of binge methamphetamine exposure and RTL treatment on cognitive function.

| Treatment Group* (n) | Drug Exposure Phasea (14 Days) | Intervention Phase (5 Days) | Behavioral Phasea (6 Days) |
|----------------------|--------------------------------|-----------------------------|---------------------------|
| SAL+Veh (n=8)        | SAL, 0.9%, s.c. 4× daily        | Tris-HCl, pH=8.5, s.c., once daily | Tris-HCl, pH=8.5, s.c., once daily |
| Meth+Veh (n=8)       | Meth, 10 mg/kg, s.c. 4× daily   | Tris-HCl, pH=8.5, s.c., once daily | Tris-HCl, pH=8.5, s.c., once daily |
| SAL-RTL551 (n=8)     | SAL, 0.9%, s.c. 4× daily        | RTL551, 100 μg, s.c., once daily | RTL551, 100 μg, s.c., once daily |
| Meth+RTL551 (n=8)    | Meth, 10 mg/kg, s.c. 4× daily   | RTL551, 100 μg, s.c., once daily | RTL551, 100 μg, s.c., once daily |

*Two cohorts (n = 32 mice per cohort) were used to evaluate binge methamphetamine exposure and RTL treatment on cognitive function.

The Drug Exposure Phase was preceded by a 7-day period of social isolation for all treatment groups. During the Drug Exposure Phase, each injection was separated by two hours and treatments occurred every other day.

The Intervention and Behavioral Testing Phases overlapped such that MWM training began on the 1st day of the Intervention Phase.

doi:10.1371/journal.pone.0056306.t002
samples were used for the multiplex detection of IFN-β memory impairments in this group. However, in the Meth+RTL551 group, mice spent significantly more time in the target quadrant than in two out of the three other quadrants, indicating that RTL551 significantly attenuated the methamphetamine induced spatial memory impairments in this group.

**Evaluation of binge methamphetamine exposure and RTL treatment on cognitive function and cytokine expression**

A neurotoxic, binge-level methamphetamine exposure model was used to more comprehensively model the human experience with methamphetamine and ultimately test the efficacy of RTL in reducing the more enduring methamphetamine-induced cognitive deficits [48,51]. Consistent with our previous results, methamphetamine exposure induced significant spatial memory impairments in mice. Kruskal-Wallis tests revealed no significant treatment group differences across study groups in terms of the latency to find the platform during the visible platform training sessions [Days 1 and 2; p = 0.39 (Gaussian approximation)] (Fig. 2A). This demonstrated that the groups were not significantly different in terms of basic motor function and perceptual abilities after treatment. Similar analyses also revealed no significant differences across treatment groups in terms of latency to find the platform during the hidden platform sessions [Days 3–5; p = 0.39 (Gaussian approximation)], suggesting that all groups were able to learn the task.

Immunotherapy with RTL significantly attenuated methamphetamine induced spatial memory impairments in mice as measured by quadrant preference during the Day 5 probe trial (i.e., the last day of hidden platform training) (Fig. 2B). Statistical analyses revealed significant differences between the target and the three non-target quadrants for the following treatment groups: 1) Sal+Veh: Target versus Quadrants 1 (p < 0.001), 2) (p < 0.01), 3) Sal+RTL551: Target versus Quadrants 1 (p < 0.05), 2) (p < 0.01), and 3) (p < 0.01). In the Meth+Veh group, the percent time spent in each of the quadrants was only statistically different between quadrant 1 and the target quadrant, indicating that methamphetamine had induced significant memory impairments in this group. However, in the Meth+RTL551 group, mice spent significantly more time in the target quadrant than in all three of the other quadrants, indicating that RTL had significantly attenuated the methamphetamine induced spatial memory impairments in this group.

To evaluate changes in CNS cytokine levels, hypothalamic samples were used for the multiplex detection of IFN-γ, IL-10, IL-1β, IL-2, IL-6, MCP-1, and TNF-α. Cytokine differences across treatment groups were analyzed using Kruskal-Wallis tests, and IL-2 was the only cytokine to show a significant effect of treatment (p = 0.028) (Table S2). Post hoc tests indicated that the Meth+Veh group had significantly higher levels of IL-2, as compared with the Sal+Veh (p = 0.007) and Meth+RTL551 (p = 0.032) groups.

**Discussion**

This study evaluated a partial MHC/neuroantigen peptide construct (RTL551; pL-A/β/mMOG-35-55), as a novel treatment strategy for methamphetamine induced cognitive impairments. The results of these experiments demonstrated that RTL551 has a treatment effect for memory impairments induced by repeated methamphetamine exposure. This treatment effect was demonstrated in two different mouse models of methamphetamine addiction (i.e., 4 mg/kg/day and 40 mg/kg/day). We initially evaluated the efficacy of RTL551 when administered during continued methamphetamine exposure; humans frequently relapse during addiction treatment [45], so it is important to understand how treatments impact outcomes in a model of relapse and active use. We subsequently evaluated the efficacy of RTL551 administered during remission from repeated binge methamphetamine exposure; this treatment regimen closely models an optimal intervention strategy in humans where the goal is to treat persistent neuropsychiatric symptoms during remission from methamphetamine dependence. In all experiments, RTL551 successfully attenuated methamphetamine induced memory impairments in mice. Moreover, mice tolerated both methamphetamine exposure models and RTL551 treatment without apparent difficulty.

Treatment with partial MHC class II constructs (also referred to as recombinant T-cell receptor ligands - RTL) linked to antigenic peptides inhibit recruitment of inflammatory cells to brain [38]. It was recently reported that a novel regulatory pathway that involves RTL binding to CD11b+ mononuclear cells through a receptor comprised of MHC class II invariant chain (CD74), cell-surface histones, and MHC class II may be contributing to its therapeutic effects [52]. Binding of RTL constructs with CD74 appears to involve MHC class II-α/CD74 interactions that inhibit CD74 expression, block activity of its ligand, macrophage migration inhibitory factor (MIF), and reduce inflammation [52]. MIF is a product of the anterior pituitary gland and has been described as: 1) a putative peptide released during the physiological stress response, 2) a pro-inflammatory cytokine secreted after lipopolysaccharide (LPS) stimulation, and 3) a T cell product expressed as part of the antigen-dependent immune response. MIF also antagonizes glucocorticoid inhibition of T-cell proliferation by restoring IL-2 and IFN-γ production [53,54].

Therefore, as an initial step toward understanding how RTL551 may impact brain function in the context of methamphetamine use, we measured the expression of pro- and anti-inflammatory cytokines in the hypothalamus following exposure to methamphetamine (or saline) and treatment with RTL551 (or vehicle). The hypothalamic-pituitary-adrenal (HPA) axis plays a critical role in the control of inflammation, and the hypothalamus, in particular, is a key brain region for CNS-to-periphery interactions and one that shows significant damage and altered functioning following methamphetamine exposure [55–57], including morphological changes and enhanced cortisol secretion that can contribute to the persistent neuropsychiatric impairments following methamphetamine use [56]. RTL inhibition of MIF signaling may help to reduce inflammation following methamphetamine exposure (and other brain insults). Consistent with this hypothesis, we found that levels of IL-2 (a potent T cell growth factor) were significantly higher in hypothalamic samples from methamphetamine exposed mice treated with vehicle, as compared with: 1) saline exposed mice, and 2) methamphetamine exposed mice treated with RTL551, suggesting that RTL551 may have contributed to a reduction in hypothalamic IL-2 levels in mice exposed to methamphetamine.

In experimental models of other neuroinflammatory conditions such as multiple sclerosis and stroke, pMHC/neuroantigen peptide constructs have been shown to successfully: 1) repair myelin and axonal damage back to baseline levels prior to disease induction, 2) reduce numbers of infiltrating inflammatory cells in the central nervous system, 3) reduce expression of intracellular adhesion molecule and vascular adhesion molecule on vascular endothelial cells, likely contributing to the reduction in infiltrating inflammatory cells, 4) reduce levels of inflammatory cytokines,
chemokines, and chemokine receptors, 5) reduce infarct size following middle cerebral artery occlusion, and 6) prevent or reverse clinical disease signs [38,39,40,41]. These findings and our own results suggest that pMHC/neuroantigen peptide constructs may help heal the brain following addiction and treat the immunological and neuropsychiatric impairments that persist for humans during remission from addiction [37].

To date, pharmacotherapeutic development for stimulant addiction has primarily focused on: 1) dopamine reuptake inhibitors (e.g., bupropion) and other dopaminergic agents to chemically block the reward associated with drug taking, 2) antidepressants, anxiolytics, or antipsychotics to reduce psychiatric symptoms such as depression or anxiety during withdrawal and early remission from addiction, and 3) medications [e.g., ondansetron, a serotonin receptor antagonist (5-HT3)] to reduce cravings and withdrawal symptoms. A recent review added to this list by summarizing the literature on cognitive enhancers which primarily target the cholinergic and noradrenergic systems [58]. One key drawback of neurotransmitter based therapies is that alone they do not offer a mechanism for repairing stimulant-induced neuronal injury—which might be vital for successful recovery. Agents specifically designed to repair neuronal damage may have increased potential to help adults regain lost function (i.e., improved cognition and mood), re-engage in meaningful work and relationships, and avoid relapse [37]. Unfortunately, the results from clinical trials continue to be disappointing, with only marginally improved outcomes and high relapse rates [6,59,60]. Further, long-term use of many of these medications may not be optimal given their abuse potential (e.g., methylenidate, modafinil [61]).

Conclusions

Our initial experiments suggest that a partial MHC/neuroantigen peptide construct (RTL551) can improve cognitive functioning and may also reduce IL-2 levels in the hypothalamus in mice exposed to methamphetamine. These results indicate that neuroimmune targeted therapies, and specifically MOG based RTLs, may have potential as treatments for methamphetamine-induced neuropsychiatric impairments.

Limitations of this study included the use of only one behavioral task, a single dose strength for RTL, and relatively small sample sizes. Future studies may also examine the effects of RTL treatment on other methamphetamine induced psychiatric impairments (e.g., depression and anxiety) and addictive behaviors (e.g., drug-seeking and relapse).

Supporting Information

Table S1 Body weight information. (DOCX)

Table S2 Cytokine expression in the hypothalamus following methamphetamine exposure and RTL treatment. (DOCX)

Acknowledgments

The authors would like to thank Drs. Gregory Burrows and Roberto Meza-Romero for providing the partial MHC constructs and Drs. John Marshall and Bryan Yamamoto for valuable consultations.

Author Contributions

Provided critical review of the manuscript: CJW AAV MH. Conceived and designed the experiments: JML AAV MH. Performed the experiments: JML CJW. Analyzed the data: JML CJW MH. Contributed reagents/materials/analysis tools: AAV CJW MH. Wrote the paper: JML.

References

1. Hoffman WF, Moore M, Templin R, McFarland B, Hitzenmann RJ, et al. (2006) Neuropsychological function and delay discounting in methamphetamine-dependent individuals. Psychopharmacology (Berl) 188: 162–170.

2. Scott JC, Woods SP, Matt GE, Meyer RA, JTC. et al. (2007) Neurocognitive effects of methamphetamine: a critical review and meta-analysis. NeuroPsychol Rev 17: 275–297.

3. Darke S, Kaye S, McKetin R, Duflou J (2008) Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev 27: 253–262.

4. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, et al. (2010) Psychopathology in methamphetamine-dependent adults 3 years after treatment. Drug Alcohol Rev 29: 12–20.

5. Louton ED, Simon SL, Berman SM, Mandell AM, Lichtman AM, et al. (2004) Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry 61: 73–84.

6. Shopfart S, Peck J, Rebach C, Rotherman-Fuller E (2003) Psychiatric and substance dependence comorbidities, sexually transmitted diseases, and risk behaviors among methamphetamine-dependent gay and bisexual men seeking outpatient drug abuse treatment. J Psychoactive Drugs 35 Suppl 1: 161–168.

7. Zewhen JE, Cohen JB, Christian D, Galloway GP, Salinardi M, et al. (2004) Psychiatric symptoms in methamphetamine users. Am J Addict 13: 181–190.

8. McLellan AT, Lewis DC, O’Brien GP, Kleber HD (2000) Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 284: 1689–1695.

9. Berman S, O’Neill J, Fears S, Bartozkoski G, London ED (2000) Abuse of amphetamines and structural abnormalities in the brain. Ann N Y Acad Sci 1114: 193–220.

10. Hoffman WF, Schwartz DL, Huckans MS, McFarland BH, Meiri G, et al. (2000) Cortical activation during delay discounting in abstinent methamphetamine-dependent individuals. Psychopharmacology (Berl) 201: 183–193.

11. Schwartz DL, Mitchell AD, Lathua DL, Luber HS, Huckans MS, et al. (2010) Global and local morphometric differences in recently abstinent methamphetamine-dependent individuals. Neuroimage 50: 1392–1401.

12. In SW, Son EW, Rhee DK, Pyo S (2005) Methamphetamine administration produces immunomodulation in mice. J Toxicol Environ Health A 68: 2133–2143.

13. In SW, Son EW, Rhee DK, Pyo S (2005) Methamphetamine administration produces immunomodulation in mice. J Toxicol Environ Health A 68: 2133–2143.

14. Liang H, Wang X, Chen H, Song L, Ye L, et al. (2008) Methamphetamine enhances HIV infection of macrophages. Am J Pathol 172: 1617–1624.

15. Martinez LR, Milhu MR, Gacer A, Santambrogio L, Nosanchuk JD (2009) Methamphetamine enhances histoplasmosis by immunosuppression of the host. J Infect Dis 200: 131–141.

16. Ye L, Peng JS, Wang X, Wang YJ, Luo GX, et al. (2008) Methamphetamine enhances Hepatitis C virus replication in human hepatocytes. J Viral Hepat 15: 261–270.

17. Silverstein PS, Shah A, Gupte R, Liu X, Phippo RW, et al. (2011) Methamphetamine toxicity and its implications during HIV-1 infection. J Neurovirol 17: 401–415.

18. Shah A, Silverstein PS, Singh DP, Kumar A (2012) Involvement of metabolotropic glutamate receptor 3, AKT/PDK signaling and NF-kappaB pathway in methamphetamine-mediated increase in IL-6 and IL-8 expression in astrocytes. J Neuroinflammation 9: 52.

19. Lofitis JM, Choi D, Hoffman W, Huckans MS (2011) Methamphetamine causes persistent immune dysregulation: a cross-species, translational report. Neurotox Res 20: 59–68.

20. Yamamoto BK, Moszcynska A, Gudelsky GA (2010) Amphetamine toxicities: classical and emerging mechanisms. Ann N Y Acad Sci 1187: 101–121.

21. Yamamoto BK, Raudensky J (2008) The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse. J Neuroimmune Pharmacol 3: 203–217.

22. Wisor JP, Schmidt MA, Clegern WC (2011) Cerebral microglia mediate sleep/wake and neuroinflammatory effects of methamphetamine. Brain Behav Immun 25: 767–776.

23. Wires KS, Alvezas D, Dobrowolski C, Wang Y, Morales M, et al. (2012) Methamphetamine activates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) and induces human immunodeficiency virus (HIV) transcription in human microglial cells. J Neurovirol.
41. Wang C, Gold BG, Kaler LJ, Yu X, Afentoulis ME, et al. (2006) Antigen-specific
40. Vandenbark AA, Rich C, Mooney J, Zamora A, Wang C, et al. (2003)
39. Subramanian S, Zhang B, Kosaka Y, Burrows GG, Grafe MR, et al. (2009)
37. Loftis JM, Huckans M (2011) Cognitive enhancement in combination with
36. Thomas DM, Walker PD, Benjamins JA, Geddes TJ, Kuhn DM (2004)
35. Sekine Y, Ouchi Y, Sugihara G, Takei N, Yoshikawa E, et al. (2008)
31. Mahajan SD, Aalinkeel R, Sykes DE, Reynolds JL, Bindukumar B, et al. (2008)
30. Kuroda KO, Ornthanalai VG, Kato T, Murphy NP (2010) FosB null mutant
28. Cloak CC, Ernst T, Fujii L, Hedemark B, Chang L (2009) Lower diffusion in
27. Chung A, Lyoo IK, Kim SJ, Hwang J, Bae SC, et al. (2007) Decreased frontal
26. Bowyer JF, Ali S (2006) High doses of methamphetamine that cause disruption
25. Bae SC, Lyoo IK, Sung YH, Yoo J, Chung A, et al. (2006) Increased white
matter hyperintensities in male methamphetamine abusers. Drug Alcohol
Depend 81: 83–88.
24. Albertson DS, Pruetz B, Schmidt CJ, Kuhn DM, Kapatas G, et al. (2004) Gene
expression profile of the nucleus accumbens of human cocaine abusers: evidence for
dysregulation of myelin. J Neurochem 88: 1211–1219.
23. Bae SC, Lyoo IK, Sung YH, Yoo J, Chung A, et al. (2006) Increased white
matter hyperintensities in male methamphetamine abusers. Drug Alcohol
Depend 81: 83–88.
22. Bowyer JJ, Ali S (2006) High doses of methamphetamine that cause disruption
of the blood-brain barrier in limbic regions produce extensive neuronal
degeneration in mouse hippocampus. Synapse 60: 521–532.
21. Chung A, Lyoo IK, Kim SJ, Hwang J, Bae SC, et al. (2007) Decreased frontal
white matter integrity in abstinent methamphetamine abusers. Int J Neuropsychopharmacol 10: 765–773.
20. Goncalves J, Baptista S, Martins T, Millazes N, Borges F, et al. (2010)
Methamphetamine-induced neuroinflammation and neuronal dysfunction in the
mice hippocampus: preventive effect of indomethacin. Eur J Neurosci 31: 315–326.
19. Kuroda KO, Ornthanalai VG, Kato T, Murphy NP (2010) FosB null mutant
mice show enhanced methamphetamine neurotoxicity: potential involvement of FosB in intracellular feedback signaling and astrogial function. Neuropharmacology 33: 641–655.
18. Mahajan SD, Aalinkeel R, Sykes DE, Reynolds JL, Bindukumar B, et al. (2008)
Methamphetamine alters blood brain barrier permeability via the modulation of
tight junction expression: Implication for HIV-1 neuropathogenesis in the
context of drug abuse. Brain Res 1203: 135–141.
17. Ok HS, Lyoo IK, Sung YH, Hwang J, Kim J, et al. (2005) Shape changes of the
capillary and sinusoids in abstinent methamphetamine users. Neurosci Lett 376: 76–80.
16. Ramirez SH, Potula R, Fan S, Edem T, Papauni A, et al. (2009)
Methamphetamine disrupts blood-brain barrier function by induction of
oxidative stress in brain endothelial cells. J Cereb Blood Flow Metab 29: 1933–1943.
15. Salo R, Nordahl TE, Buonocore MH, Natsuki Y, Waters C, et al. (2009)
Cognitive control and white matter callosal microstructure in methamphetamine-
abuse-dependent subjects: a diffusion tensor imaging study. Biol Psychiatry 65: 529–538.
14. Sekine Y, Ouchi Y, Sugihara G, Takei N, Yoshikawa E, et al. (2008)
Methamphetamine causes microglial activation in the brains of human abusers. J Neurosci 28: 5756–5761.
13. Siddiqui DM, Wilner PD, Benjamin JA, Geddes TJ, Kuhn DM (2004)
Methamphetamine neurotoxicity in dopamine nerve endings of the striatum
is associated with microglial activation. J Pharmacol Exp Ther 311: 1–7.
12. Loftis JM, Huckans M (2011) Cognitive enhancement in combination with
‘brain repair’ may be optimal for the treatment of stimulant addiction. Addiction 106: 1021–1022.
11. Sinha S, Subramanian S, Miller L, Proctor TM, Roberts C, et al. (2009)
Cytokine switch and bystander suppression of autoimmune responses to multiple
antigens in experimental autoimmune encephalomyelitis by a single recombi-
nant T-cell receptor ligand. J Neurosci 29: 3016–3023.
10. Huckman MS, Wilhelm CJ, Huan J, Vandenbark AA, Lofts JM (2011) RT551:
A potential neuroimmune-based treatment for methamphetamine addiction.
Brain, Behavior & Immunity 25: 822–7.
9. Duvoisin RM, Villasana L, Plunkott T, Raper J (2010) Sex-dependent cognitive
phenotype of mice lacking mGluR8. Behav Brain Res 209: 21–26.
8. Newton TF, De La Garza R Jr, Kalcehstein AD, Tzorozitis D, Jacobsen CA
(2009) Theories of addiction: methamphetamine users’ explanations for
continuing drug use and relapse. Am J Addict 18: 294–300.
7. Remoules M, Schuman EM (2004) Role for a cortical input to hippocampal
area CA1 in the consolidation of a long-term memory. Nature 431: 699–703.
6. Dai H, Okuda H, Iwabuchi K, Sakurai E, Chen Z, et al. (2004) Social isolation
stress significantly enhanced the disruption of preprohormone injection in mice
repeatedly treated with methamphetamine. Ann N Y Acad Sci 1025: 257–266.
5. Jia F, Moharabek JI, Dai H, Kato M, Xu A, et al. (2008) Blocking histamine
H1 improves learning and mnemonic dysfunction in mice with social isolation
plus repeated methamphetamine injection. J Pharmacol Sci 107: 167–174.
4. Huie RE, Kunkler PE, Fedynnyshyn JP, Kraig RP (2004) Optimization of
multipleplex bead-based cytokine immunoassays for rat serum and brain tissue. J Neurosci Methods 136:67–98.
3. Wilheim CJ, Murphy-Creasy A, Menasco DJ, Hukkan MS, Lofts JM (2012)
Cocitocin releasing factor-1 receptor antagonist alters the biochemical, but not
behavioral effects of repeated interleukin-1β administration. Neuropharma-
cology 2012. Jan 5:211–312.
2. Madden LJ, Flynn CT, Zandozanti MA, May M, Parsons LH, et al. (2005)
Modeling human methamphetamine exposure in nonhuman primates: chronic
dosing in the rhesus macaque leads to behavioral and physiological
abnormalities. Neuropsychopharmacology 30: 350–359.
1. Vandenbark AA, Meza-Roverso R, Benedek G, Andrew S, Huan J, et al. (2012)
A novel regulatory pathway for autoimmune disease: Binding of partial MHC
class II constructs to monocytes reduces CD74 expression and induces both
specific and bystander T-cell tolerance. J Autoimmun. Epub ahead of print.
1. Calandra T, Spiegel LA, Metz CN, Bucala R (1990) Macrophage migration
inhibitory factor is a critical mediator of the activation of immune cells by
exotoxins of Gram-positive bacteria. Proc Natl Acad Sci USA 95:1303–8.
1. Calandra T, Bucala R (1997) Macrophage migration inhibitory factor (MIF): a
glucocorticoid counter-regulator within the immune system. Crit Rev Immunol 17:77–88.
1. King G, Alatic D, Cloak C, Chang L (2010) Psychiatric symptoms and HPA
axis function in adolescent methamphetamine users. J Neuroimmun Pharmaco- 5:258–591.
1. Carson DS, Hunt GE, Guattella AJ, Barber L, Cornish J, et al. (2010) Systemically
administered oxytocin decreases methamphetamine activation of the
subthalamic nucleus and accumbens core and stimulates oxytocinergic
neurons in the hypothalamus. Addict Biol 15, 448–463.
1. Sharma HS, Kiyatkin EA (2009) Rapid morphological brain abnormalities
during acute methamphetamine intoxication in the rat: an experimental study
using light and electron microscopy. J Chem Neuroanat 37, 18–32.
1. Sofuoglu M (2010) Cognitive enhancement as a pharmacotherapy target for
stimulant addiction. Addiction 105: 38–48.
1. Heinzerling KG, Swanson AN, Kim S, Cederblom L, Moe A, et al. (2010)
Randomized, double-blind, placebo-controlled trial of modafinil for the
management of methamphetamine dependence. Drug Alcohol Depend 109: 20–29.
1. Johnson BA, Ait-Daoud N, Elkashef AM, Smith EV, Kahn R, et al. (2008) A
decay of cell surface MHC class II expression during acute methamphetamine
intoxication in the rat: an experimental study using light and electron microscopy. J Chem Neuroanat 37, 18–32.
1. Meddill DS, Hunte CE, Gunatilleke AE, Logan J, Aitoff D, Zhu W, et al. (2009) Effects of
modafinil on dopamine and dopamine transporters in the male human brain:
clinical implications. JAMA 301:1148–1154.